Harnessing the Power of TCR-T Cell Therapy: A New Era in Cancer Immunotherapy

The authors discuss the FDA’s approval of “afami-cel,” a first-in-class gene-modified autologous T cell therapy, for the treatment of specific solid tumor indications.